Also trades as: 0JDK.L (LSE) · $vol 3M
IOVA NASDAQ
Iovance Biotherapeutics, Inc.
1W: -3.0%
1M: +25.3%
3M: +193.2%
YTD: +446.8%
1Y: +529.2%
3Y: +317.6%
5Y: -46.0%
$14.58
+0.80 (+5.81%)
Weekly Expected Move ±18.3%
$9
$12
$14
$17
$19
Credit Risk of going bust: lower than 52% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.24B.
Distance to default 5.28 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.3%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.24B.
Distance to default 5.28 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.3%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$264M
+60.6% ▲
Gross Profit
$256M
+539.3% ▲
Operating Income
-$403M
-2.0% ▼
Net Income
-$391M
-5.1% ▼
EPS (Diluted)
$-1.09
+14.8% ▲
EBITDA
-$357M
-1.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1M | $164M | $264M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +13699.0% | +60.6% |
| Cost of Revenue | $0 | $0 | $11M | $124M | $7M |
| Gross Profit | $0 | $0 | -$10M | $40M | $256M |
| Gross Margin | — | — | -804.5% | 24.4% | 97.2% |
| R&D Expenses | $259M | $295M | $344M | $282M | $300M |
| SG&A Expenses | $84M | $104M | $107M | $153M | $152M |
| Operating Expenses | $343M | $399M | $451M | $435M | $660M |
| Operating Income | -$343M | -$399M | -$461M | -$395M | -$403M |
| Operating Margin | — | — | -38735.0% | -240.9% | -153.1% |
| Interest Expense | $0 | $3M | $0 | $0 | $0 |
| Income Before Tax | -$342M | -$396M | -$448M | -$375M | -$393M |
| Tax Expense | $0 | $0 | -$3M | -$3M | -$2M |
| Net Income | -$342M | -$396M | -$444M | -$372M | -$391M |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Diluted) | $-2.23 | $-2.49 | $-1.89 | $-1.28 | $-1.09 |
| EBITDA | -$329M | -$378M | -$427M | -$352M | -$357M |
| Shares Outstanding | 153M | 159M | 235M | 290M | 357M |